- Taysha Gene Therapies recently announced a commercial supply agreement under which Catalent will serve as the primary commercial manufacturer of TSHA-102, its investigational Rett syndrome gene therapy, at Catalent’s FDA-licensed facility in Harmans, Maryland, securing long-term GMP capacity to support potential U.S. launch and future demand.
- This move effectively locks in a scalable manufacturing backbone for TSHA-102, signaling that Taysha is preparing its operations for possible commercialization beyond the current pivotal development stage.
- With this commercial supply agreement now in place, we’ll examine how securing long-term TSHA-102 manufacturing capacity could reshape Taysha’s investment narrative.
Find 51 companies with promising cash flow potential yet trading below their fair value.
Taysha Gene Therapies Investment Narrative Recap
To own Taysha Gene Therapies, you need to believe TSHA-102 can move from promising Rett syndrome data to an approved, commercially viable product before cash pressure bites. The Catalent supply deal directly addresses one of the biggest operational risks by securing GMP capacity, but it does not change the near term clinical and regulatory catalyst around the REVEAL pivotal data and the timing of an eventual BLA filing, which remain central to the story.
Among recent announcements, the June 24 follow on equity raise of about US$200.0 million stands out beside the Catalent agreement. Together, they highlight a company committing capital to both manufacturing and commercialization while still loss making, with Q1 2026 net loss at about US$42.4 million. That combination increases the importance of upcoming TSHA-102 data and FDA feedback as potential value inflection points for shareholders.
Yet behind the commercial build out, investors should also be aware that any delay in pivotal data or BLA timing could force further equity raises and possible...
Read the full narrative on Taysha Gene Therapies (it's free!)
Taysha Gene Therapies' narrative projects $233.1 million in revenue and $44.1 million in earnings by 2029. This requires 214.8% yearly revenue growth and a $174.0 million earnings increase from -$129.9 million today.
Uncover how Taysha Gene Therapies' forecasts yield a $12.85 fair value, a 102% upside to its current price.
Exploring Other Perspectives
Optimistic analysts were already modeling revenue of about US$370.0 million and a swing to roughly US$46.4 million in earnings by 2029, so this Catalent deal could either support that bullish path or highlight how sensitive those expectations are to clinical progress and regulatory decisions.
Explore 4 other fair value estimates on Taysha Gene Therapies - why the stock might be worth over 9x more than the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Taysha Gene Therapies research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Taysha Gene Therapies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Taysha Gene Therapies' overall financial health at a glance.
Ready For A Different Approach?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com